Iter-4360dd15-0030-transcript
第 30 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 rapamycin review DOI Table 1 full text"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0025-transcript", "tags": "iteration transcript", "modified": "20260424183856000", "preview": "!! 第 25 轮执行轨迹
→ call search_memory({\\\"limit\\\":8,\\\"query\\\":\\\"4360dd15 rapamycin review 2024 tri"}, {"title": "Iter-4360dd15-0010-transcript", "tags": "iteration transcript", "modified": "20260424175830000", "preview": "!! 第 10 轮执行轨迹 → cal"}, {"title": "Iter-4360dd15-0011-transcript", "tags": "iteration transcript", "modified": "20260424180153000", "preview": "!! 第 11 轮执行轨迹 → call list_recent({"n":8})
→ call list_by_tag({"limit":20,"tag":"4360dd15"})
→ call list_tools({})
【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0029-reflection", "modified": "20260424185116000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424185116000", "tags": "pinned focus"}, {"title": "先锁具体入口，再谈全文", "modified": "20260424185116000", "tags": "lesson evidence-retrieval full-text paywall"}, {"title": "Iter-4360dd15-0029-transcript", "modified": "20260424185112000", "tags": "iteration transcript"}, {"title": "Error-20260425-024620", "modified": "20260424184620000", "tags": "error iteration"}, {"title": "Iter-4360dd15-0027-reflection", "modified": "20260424184550000", "tags": "iteration reflection"}, {"title": "先用题名+DOI锁入口", "modified": "20260424184550000", "tags": "lesson evidence-retrieval full-text paywall"}, {"title": "Iter-4360dd15-0027-transcript", "modified": "20260424184545000", "tags": "iteration transcript"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "2024 rapamycin systematic review: abstract-level constraints and what remains missing", "modified": "20260424175824000"}, {"title": "Added included ADPKD rapalog trial CRAD001ADE12 and its body-weight endpoint", "modified": "20260424174657000"}, {"title": "Rapamycin human trials: completed studies table from PMC review", "modified": "20260424174352000"}, {"title": "Iter-4360dd15-0004-critique-rapamycin-evidence", "modified": "20260424174226000"}, {"title": "Rapamycin human trials: extracted endpoints and outcomes from the 2024 systematic review review pass 1", "modified": "20260424173529000"}, {"title": "Human longevity interventions evidence maturity matrix 2026-04-25", "modified": "20260424173237000"}]}
【tool:list_tools】
{"ok": true, "tools": [{"name": "search_memory", "description": "在 TiddlyWiki 长期记忆中按关键字搜索（支持中文空格分隔），返回标题、标签、预览。每轮迭代开始前应先调用以回忆。", "custom": false}, {"name": "read_note", "description": "读取某一条 tiddler 的完整正文。", "custom": false}, {"name": "write_note", "description": "向 TiddlyWiki 写入（或覆盖）一条 tiddler。这是 Sisyphus 的长期记忆入口——每轮至少写一条。建议标签：knowledge, experiment, reflection, plan, idea, fact, question, lesson。TiddlyWiki 标记：!! 小标题，''粗体''，斜体，其它tiddler。", "custom": false}, {"name": "list_recent", "description": "列出最近修改过的 tiddler。", "custom": false}, {"name": "list_by_tag", "description": "按标签列出相关 tiddler。", "custom": false}, {"name": "run_python", "description": "在 workspace/ 下以子进程执行一段 Python 代码，返回 stdout/stderr。用于计算、模拟、验证假设、抓取公开数据（禁止任何破坏性操作）。", "custom": false}, {"name": "read_file", "description": "读取 workspace/ 下的某个文件。", "custom": false}, {"name": "write_file", "description": "向 workspace/ 下写入文件（默认覆盖，append=true 时追加）。", "custom": false}, {"name": "list_files", "description": "列出 workspace/ 下的文件。", "custom": false}, {"name": "web_fetch", "description": "抓取任意公开 URL（GET），返回剥离 HTML 后的纯文本。适合读论文摘要、文档、博客、百科。", "custom": false}, {"name": "web_search", "description": "用 DuckDuckGo 搜索互联网，返回 title/url/snippet 列表。找入口、找链接、调研时用。", "custom": false}, {"name": "wiki_search", "description": "维基百科搜索：返回若干条目的摘要和 URL。lang 默认 en，可传 zh 等。", "custom": false}, {"name": "arxiv_search", "description": "arXiv 论文检索：标题/作者/摘要/链接。理论、数学、物理、CS、bio 类前沿论文的主入口。", "custom": false}, {"name": "pubmed_search", "descriptio
→ call search_memory({"limit":8,"query":"4360dd15 rapamycin systematic review ResearchGate DOI PMID title"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0010-transcript", "tags": "iteration transcript", "modified": "20260424175830000", "preview": "!! 第 10 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 rapamycin review 2024 trial endpoint remaining 11\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0007-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424174944000\", \"preview\": \"!! 第 7 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 rapamycin 2024 systematic review 19 studies Table 1 included trials endpoint\"}) → call list_recent({\"n\":6}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0010-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424175830000\", \"preview\": \"!! 第 10 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 rapamycin 2024 systematic review 19 studies Table 1全文 镜像\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0010-transcript\", \"tags\" → call read_note({"title":"2024 rapamycin systematic review: abstract-level constraints and what remains missing"})
→ call read_note({"title":"Rapamycin human trials: completed studies table from PMC review"})
→ call read_note({"title":"Human longevity interventions evidence maturity matrix 2026-04-25"})
【tool:read_note】
{"ok": true, "title": "2024 rapamycin systematic review: abstract-level constraints and what remains missing", "tags": "lesson fact 4360dd15 [[evidence retrieval]]", "text": "!! What I could verify this round\nI could not yet recover the remaining 11 included-study names from the 2024 systematic review, but I did verify the paper’s abstract via PubMed XML and extracted a few important constraints.\n\n!! Verified bibliographic identity\n- PMID: 38310895\n- Title: ''Targeting ageing with rapamycin and its derivatives in humans: a systematic review.''\n- Journal: //Lancet Healthy Longev// 2024 Feb; 5(2):e152-e162\n- DOI: 10.1016/S2666-7568(23)00258-1\n\n!! Abstract-level findings worth retaining\nThe abstract states that:\n# 18,400 unique articles were screened\n# 19 studies were included\n# benefits were observed in the immune, cardiovascular, and integumentary systems\n# no significant effects were found in the endocrine, muscular, or neurological systems\n# respiratory, digestive, renal, and reproductive systems were not assessed\n# no serious adverse events attributed to rapamycin/derivatives were reported in healthy individuals\n# in individuals with ageing-related diseases, infections and lipid increases were reported\n\n!! Why this matters\nThis is stronger than a generic \"rapamycin is anti-aging\" claim, but still weaker than a study-level map. The review’s abstract already tells us the evidence is:\n- multi-system but fragmented\n- partly positive in healthy or ageing-
【tool:read_note】
{"ok": true, "title": "Rapamycin human trials: completed studies table from PMC review", "tags": "knowledge fact 4360dd15", "text": "!! PMC review Table 1: completed human rapamycin / rapalog trials\n\nI re-read the accessible PMC review [[Blazing a trail for the clinical use of rapamycin as a geroprotecTOR]] (GeroScience 2023; PMCID PMC10643772) and extracted its completed-trial table.\n\n!! What this source actually contains\nThe table lists ''8 completed human studies'' and gives each study’s primary endpoint.\n\n!! Extracted trial list\n| Study | Agent | Population | Primary endpoint |\n|---|---|---|---|\n| Krebs et al. 2007 | rapamycin | 11 men, 28 ± 1 y | Increase in peripheral insulin sensitivity during insulin clamp plus amino acid infusion |\n| Drummond et al. 2009 | rapamycin | 15 men, 29 ± 2 y | Difference in post-resistance-exercise mixed-muscle protein synthesis rates |\n| Gunderman 2014 | rapamycin | 16 men, 26 ± 1 y | Difference in post-blood-flow-restricted resistance-exercise mixed-muscle protein synthesis rates |\n| Mannick et al. 2014 | everolimus | 218 adults ≥65 y | Improvement in influenza vaccination response |\n| Mannick et al. 2018 | everolimus / BEZ235 | 264 adults ≥65 y | Improvement in influenza vaccination response |\n| Kraig et al. 2018 | rapamycin | 25 healthy adults 70–95 y | Immunological response |\n| Chung et al. 2019 | topical rapamycin | 36 adults with aging skin >40 y | Decreased p16-positive senescent cells in skin |\n| Mannick et al. 20
【tool:read_note】
{"ok": true, "title": "Human longevity interventions evidence maturity matrix 2026-04-25", "tags": "knowledge fact experiment 4360dd15", "text": "!! 人类长寿干预的证据成熟度矩阵（初版）\n\n本轮子任务：把“如何让人类长生不老”压缩成一个可比较的系统问题：哪些干预已经进入//人类//临床证据层，哪些仍主要停留在机制层。\n\n!! 结论（按当前公开检索证据）\n# ''rapamycin / mTOR''：最高成熟度之一。\n## 证据\n- ClinicalTrials.gov 的随机、双盲、安慰剂对照试验：NCT04488601（间歇性 rapamycin，每周给药）\n- Lancet Healthy Longevity 综述：检索 5 个数据库后纳入 19 项研究，报告其可改善健康相关生理参数（免疫、心血管、皮肤等）\n- Cell Metabolism 2023 综述把 TORC1 inhibitors 列为已进入临床测试的抗衰老药物之一\n\n# ''senolytics''：最高成熟度之一。\n## 证据\n- ClinicalTrials.gov NCT04313634：针对 senolytics 改善骨骼肌/活动能力的研究方案\n- 另检到 NCT05422885、NCT05276895 等活跃临床试验条目\n- 2025 年 Nature 文章提示 senolytic 试验正朝更个体化方向发展\n\n# ''NAD+ boosters''：中等成熟度。\n## 证据\n- Nat Aging 2025 综述：\"Emerging strategies, applications and challenges of targeting NAD(+) in the clinic\"\n- Cell Metabolism 2023 综述将 NAD+ precursors 纳入已被临床测试的抗衰老候选物\n- 但本轮没有检到足够明确的“以衰老本身为终点”的试验条目\n\n# ''partial reprogramming''：机制潜力高，但人类临床证据最弱。\n## 证据\n- Ageing Research Reviews 2026 综述将其视作治疗衰老与疾病的策略\n- 本轮未检到明确的人类抗衰老临床试验条目\n- 目前更像“高潜力、低成熟度”的前沿方向\n\n!! 初版排序（仅基于本轮公开检索）\n1. rapamycin / mTOR\n2. senolytics\n3. NAD+ boosters\n4. partial reprogramming\n\n!! 方法备注\n- 本轮采用“先压缩为证据成熟度矩阵，再比较路径”的策略。\n- 指标维度：human_trials、review_depth、aging_specificity、overall_maturity。\n- 用于避免把机制上最酷的方向误判成临床上最接近“长生不老”的方向。\n\n!! 重要限制\n- 这只是“公开检索到的初版矩阵”，不是终局判断。\n- 还缺少：样本量、终点类型、随访时长、安全性、可逆性、成本/可扩展性比较。\n- 下一步应该把 top 2 路径（rapamycin vs senolytics）拆到更细的临床终点级别比较。"}
→ call web_search({"limit":8,"query":"\"Targeting ageing with rapamycin and its derivatives in humans: a systematic review\" ResearchGate"})
→ call web_search({"limit":8,"query":"\"10.1016/S2666-7568(23)00258-1\" ResearchGate"})
【tool:web_search】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://html.duckduckgo.com/html/?q=%22Targeting+ageing+with+rapamycin+and+its+derivatives+in+humans%3A+a+systematic+review%22+ResearchGate'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_search】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://html.duckduckgo.com/html/?q=%2210.1016%2FS2666-7568%2823%2900258-1%22+ResearchGate'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call pubmed_search({"limit":5,"query":"\"Targeting ageing with rapamycin and its derivatives in humans: a systematic review\""})
→ call web_fetch({"max_chars":5000,"url":"https://api.openalex.org/works/https://doi.org/10.1016/S2666-7568(23)00258-1"})
→ call web_fetch({"max_chars":5000,"url":"https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1016/S2666-7568(23)00258-1&format=json"})
【tool:pubmed_search】
{"ok": true, "query": "\"Targeting ageing with rapamycin and its derivatives in humans: a systematic review\"", "results": [{"pmid": "38310895", "title": "Targeting ageing with rapamycin and its derivatives in humans: a systematic review.", "source": "Lancet Healthy Longev", "pubdate": "2024 Feb", "authors": ["Lee DJW", "Hodzic Kuerec A", "Maier AB"], "url": "https://pubmed.ncbi.nlm.nih.gov/38310895/"}, {"pmid": "28504837", "title": "Immunotherapy for metastatic renal cell carcinoma.", "source": "Cochrane Database Syst Rev", "pubdate": "2017 May 15", "authors": ["Unverzagt S", "Moldenhauer I", "Nothacker M", "Roßmeißl D", "Hadjinicolaou AV", "Peinemann F", "Greco F", "Seliger B"], "url": "https://pubmed.ncbi.nlm.nih.gov/28504837/"}]}
【tool:web_fetch】
{"ok": true, "url": "https://api.openalex.org/works/https://doi.org/10.1016/S2666-7568(23)00258-1", "status": 200, "content_type": "application/json", "text": "{\"id\":\"https://openalex.org/W4391544908\",\"doi\":\"https://doi.org/10.1016/s2666-7568(23)00258-1\",\"title\":\"Targeting ageing with rapamycin and its derivatives in humans: a systematic review\",\"display_name\":\"Targeting ageing with rapamycin and its derivatives in humans: a systematic review\",\"publication_year\":2024,\"publication_date\":\"2024-02-01\",\"ids\":{\"openalex\":\"https://openalex.org/W4391544908\",\"doi\":\"https://doi.org/10.1016/s2666-7568(23)00258-1\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/38310895\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/s2666-7568(23)00258-1\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/s2666-7568(23)00258-1\",\"pdf_url\":\"http://www.thelancet.com/article/S2666756823002581/pdf\",\"source\":{\"id\":\"https://openalex.org/S4210210722\",\"display_name\":\"The Lancet Healthy Longevity\",\"issn_l\":\"2666-7568\",\"issn\":[\"2666-7568\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVer
【tool:web_fetch】
{"ok": true, "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1016/S2666-7568(23)00258-1&format=json", "status": 200, "content_type": "application/json;charset=UTF-8", "text": "{\"version\":\"6.9\",\"hitCount\":0,\"request\":{\"queryString\":\"DOI:10.1016/S2666-7568(23)00258-1\",\"resultType\":\"lite\",\"cursorMark\":\"*\",\"pageSize\":25,\"sort\":\"\",\"synonym\":false},\"resultList\":{\"result\":[]}}", "truncated": false}
→ call web_fetch({"max_chars":8000,"url":"http://www.thelancet.com/article/S2666756823002581/pdf"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://www.thelancet.com/article/S2666756823002581/pdf'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call search_memory({"limit":10,"query":"4360dd15 ResearchGate rapamycin systematic review"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0010-transcript", "tags": "iteration transcript", "modified": "20260424175830000", "preview": "!! 第 10 轮执行轨迹
→ cal"}, {"title": "Iter-4360dd15-0011-transcript", "tags": "iteration transcript", "modified": "20260424180153000", "preview": "!! 第 11 轮执行轨迹 → call search_memory({\\\"limit\\"}, {"title": "Iter-4360dd15-0025-transcript", "tags": "iteration transcript", "modified": "20260424183856000", "preview": "!! 第 25 轮执行轨迹 → call web_fetch({"max_chars":15000,"url":"https://api.openalex.org/works/https://doi.org/10.1016/S2666-7568(23)00258-1"})
【tool:web_fetch】
{"ok": true, "url": "https://api.openalex.org/works/https://doi.org/10.1016/S2666-7568(23)00258-1", "status": 200, "content_type": "application/json", "text": "{\"id\":\"https://openalex.org/W4391544908\",\"doi\":\"https://doi.org/10.1016/s2666-7568(23)00258-1\",\"title\":\"Targeting ageing with rapamycin and its derivatives in humans: a systematic review\",\"display_name\":\"Targeting ageing with rapamycin and its derivatives in humans: a systematic review\",\"publication_year\":2024,\"publication_date\":\"2024-02-01\",\"ids\":{\"openalex\":\"https://openalex.org/W4391544908\",\"doi\":\"https://doi.org/10.1016/s2666-7568(23)00258-1\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/38310895\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/s2666-7568(23)00258-1\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/s2666-7568(23)00258-1\",\"pdf_url\":\"http://www.thelancet.com/article/S2666756823002581/pdf\",\"source\":{\"id\":\"https://openalex.org/S4210210722\",\"display_name\":\"The Lancet Healthy Longevity\",\"issn_l\":\"2666-7568\",\"issn\":[\"2666-7568\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVer
→ call run_python({"code":"import requests, json\nurl='https://api.openalex.org/works/https://doi.org/10.1016/S2666-7568(23)00258-1'\nobj=requests.get(url,timeout=30).json()\nprint('keys', obj.keys())\nprint('best_oa_location', obj.get('best_oa_location'))\nprint('oa_url', obj.get('open_access',{}).get('oa_url'))\nprint('locations_count', obj.get('locations_count'))\nfor i,loc in enumerate(obj.get('locations',[])[:)
【tool:run_python】
{"ok": true, "stdout": "io', 'is_retracted', 'is_paratext', 'is_xpac', 'primary_topic', 'topics', 'keywords', 'concepts', 'mesh', 'locations_count', 'locations', 'best_oa_location', 'sustainable_development_goals', 'awards', 'funders', 'has_content', 'content_urls', 'referenced_works_count', 'referenced_works', 'related_works', 'abstract_inverted_index', 'counts_by_year', 'updated_date', 'created_date'])\nbest_oa_location {'id': 'doi:10.1016/s2666-7568(23)00258-1', 'is_oa': True, 'landing_page_url': 'https://doi.org/10.1016/s2666-7568(23)00258-1', 'pdf_url': 'http://www.thelancet.com/article/S2666756823002581/pdf', 'source': {'id': 'https://openalex.org/S4210210722', 'display_name': 'The Lancet Healthy Longevity', 'issn_l': '2666-7568', 'issn': ['2666-7568'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320990', 'host_organization_name': 'Elsevier BV', 'host_organization_lineage': ['https://openalex.org/P4310320990'], 'host_organization_lineage_names': ['Elsevier BV'], 'type': 'journal'}, 'license': 'cc-by', 'license_id': 'https://openalex.org/licenses/cc-by', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True, 'raw_source_name': 'The Lancet Healthy Longevity', 'raw_type': 'journal-article'}\noa_url http://www.thelancet.com/article/S2666756823002581/pdf\nlocations_count 4\nLOC 0\n{'landing_page_url': 'https://doi.org/10.1016/s2666-7568(23)00258-1', 'pdf_url': 'http://www.thelancet.com/article/S266675
→ call web_fetch({"max_chars":8000,"url":"https://research.vu.nl/en/publications/bc864430-4237-4bcd-a3b3-38b3b91b2e60"})
【tool:web_fetch】
{"ok": true, "url": "https://research.vu.nl/en/publications/targeting-ageing-with-rapamycin-and-its-derivatives-in-humans-a-s/", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Targeting ageing with rapamycin and its derivatives in humans: a systematic review - Vrije Universiteit Amsterdam Skip to main navigation Skip to search Skip to main content Vrije Universiteit Amsterdam Home Help & FAQ Link opens in a new tab Search content at Vrije Universiteit Amsterdam Home Profiles Research units Research output Courses Projects Datasets / Software Activities Prizes / Grants Press / Media Targeting ageing with rapamycin and its derivatives in humans: a systematic review Deborah J W Lee , Ajla Hodzic Kuerec , Andrea B Maier Prevention and Rehabilitation AMS - Ageing & Vitality APH - Aging & Later Life APH - Global Health Research output : Contribution to Journal › Review article › Academic › peer-review Overview Fingerprint Abstract Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on the severity of ageing-related physiological changes and disease in adults. A search across five databases yielded 18 400 unique articles, resulting in 19 included studies. Rapamycin and its derivatives improved physiological parameters associated with ageing in the immune, cardiovascular, and integumentary systems of healthy individuals or individuals with agein
→ call web_fetch({"max_chars":8000,"url":"https://hdl.handle.net/1871.1/bc864430-4237-4bcd-a3b3-38b3b91b2e60"})
【tool:web_fetch】
{"ok": true, "url": "https://research.vu.nl/en/publications/targeting-ageing-with-rapamycin-and-its-derivatives-in-humans-a-s/", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Targeting ageing with rapamycin and its derivatives in humans: a systematic review - Vrije Universiteit Amsterdam Skip to main navigation Skip to search Skip to main content Vrije Universiteit Amsterdam Home Help & FAQ Link opens in a new tab Search content at Vrije Universiteit Amsterdam Home Profiles Research units Research output Courses Projects Datasets / Software Activities Prizes / Grants Press / Media Targeting ageing with rapamycin and its derivatives in humans: a systematic review Deborah J W Lee , Ajla Hodzic Kuerec , Andrea B Maier Prevention and Rehabilitation AMS - Ageing & Vitality APH - Aging & Later Life APH - Global Health Research output : Contribution to Journal › Review article › Academic › peer-review Overview Fingerprint Abstract Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on the severity of ageing-related physiological changes and disease in adults. A search a
```